We also found evidence for an association between the EPO-increasing A allele of rs1617640 and decreased fibrosis-4 score (β = −0.01, p = 4.7 × 10−17) and non-alcoholic fatty acid liver disease (NAFLD) fibrosis score (β = −0.02, p = 2.20 × 10−25) (Figure S13, Table S14). This evidence concerns the gene EPO and metabolic dysfunction-associated steatotic liver disease.